-
Earnings call: Harvard Bioscience faces Q1 challenges, eyes H2 recovery By Investing.com
Source: Buzz FX / 07 May 2024 15:46:28 America/New_York
Harvard Bioscience (NASDAQ: [HBIO](/equities/harvard-bioscienc)) has reported a challenging first quarter for 2024, with a noticeable decline in sales, particularly in the China and Asia Pacific markets, and faced supply chain issues.
Read more...